Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
Open Access
- 22 April 2022
- journal article
- research article
- Published by Elsevier in Toxicology Reports
- Vol. 9, 927-936
Abstract
No abstract availableKeywords
Funding Information
- United States Agency for International Development
- Bill and Melinda Gates Foundation (OPP1129600)
- Irish Aid
- Department for International Development, UK Government
- Department of Foreign Affairs and Trade, Australian Government
- Bundesministerium für Forschung, Technologie und Raumfahrt
- National Institute of Allergy and Infectious Diseases
- Ministerie van Buitenlandse Zaken
This publication has 12 references indexed in Scilit:
- Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy VolunteersClinical Pharmacology in Drug Development, 2020
- Treatment of Highly Drug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2020
- Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824Antimicrobial Agents and Chemotherapy, 2012
- Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis PatientsAntimicrobial Agents and Chemotherapy, 2010
- Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2009
- The mechanism of action of PA-824Communicative & Integrative Biology, 2009
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisNature, 2000
- Dark urine related to metronidazole therapy.1971
- Dark Urine Related to Metronidazole TherapyJAMA, 1971